Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biopharmaceutical company, has announced its membership in the Biosimilars Forum, a nonprofit organization dedicated to advancing the biosimilars industry in the United States. The membership aims to expand access to biological medicines and improve healthcare outcomes. Henlius anticipates that this membership will significantly enhance the accessibility and adoption of its biosimilar products globally.
Henlius Biotech: A Global Presence in Biologics Development and Manufacturing
Henlius, with a focus on the development, manufacturing, and marketing of high-quality biologics, has established a business presence in over 50 countries, positively impacting more than 700,000 individuals worldwide. The company has an impressive track record, having launched four biosimilars: Hanquyou (trastuzumab), Hanlikang (rituximab), HanDaYuan (adalimumab), and Hanbeitai (bevacizumab). In addition to these, Henlius has more than 10 biosimilar candidates in the pipeline, including HLX11 (pertuzumab), HLX13 (ipilimumab), and HLX14 (denosumab).
The Impact of Henlius Biotech’s Biosimilars Forum Membership
By joining the Biosimilars Forum, Henlius Biotech is poised to leverage the organization’s resources and network to further the development and adoption of its biosimilar products. This move aligns with the company’s commitment to improving patient access to affordable, high-quality biologics and contributes to the global effort to enhance healthcare standards.-Fineline Info & Tech
Leave a Reply